# Efficacy Comparison Study of Combination Regimens to Treat Advanced Esophageal Squamous Cell Carcinoma

> **NCT00816634** · PHASE2 · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 94 (estimated)

## Conditions studied

- First Line Chemotherapy
- Capecitabine Plus Cisplatin Versus Capecitabine Plus Paclitaxel
- Advanced or Recurrent Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Capecitabine plus cisplatin(XP) versus capecitabine plus paclitaxel(XT)

## Key facts

- **NCT ID:** NCT00816634
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-10
- **Primary completion:** 2017-10
- **Final completion:** 2018-12
- **Target enrollment:** 94 (ESTIMATED)
- **Last updated:** 2017-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00816634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00816634, "Efficacy Comparison Study of Combination Regimens to Treat Advanced Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT00816634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*